Repligen Corporation to Present at Wells Fargo Healthcare Conference

Rhea-AI Summary

Repligen (NASDAQ:RGEN), a leading bioprocessing technology company in the life sciences sector, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The event is scheduled to take place from September 4-6 in Boston.

Olivier Loeillot, Repligen's President and CEO, will engage in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Repligen's Investor Relations website at www.repligen.com. The replay of the presentation will be available for a time after the event.

This conference provides Repligen with an opportunity to showcase its latest developments and strategic initiatives in the bioprocessing technology field to investors and industry analysts.

News Market Reaction – RGEN

-0.86%

-0.86% Session move

In the trading session that priced this news, RGEN declined 0.86%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

FAQ

When is Repligen (RGEN) presenting at the Wells Fargo Healthcare Conference?

Repligen (RGEN) is presenting at the Wells Fargo Healthcare Conference on Friday, September 6, at 8:45 a.m. ET.

Who will be representing Repligen (RGEN) at the Wells Fargo Healthcare Conference?

Olivier Loeillot, President and Chief Executive Officer of Repligen, will be representing the company at the Wells Fargo Healthcare Conference.

How can investors access Repligen's (RGEN) presentation at the Wells Fargo Healthcare Conference?

Investors can access a live webcast of Repligen's presentation through the company's Investor Relations website at www.repligen.com.

What dates is the Wells Fargo Healthcare Conference being held?

The Wells Fargo Healthcare Conference is being held from September 4-6 in Boston.

Will a replay of Repligen's (RGEN) presentation be available after the conference?

Yes, a replay of Repligen's presentation will be available for a period of time following the event on their Investor Relations website.